Conversely, in the randomized controlled Mitra-FR trial, there were no significant differences in the rate of HF hospitalizations at 12 months [48.7% vs. 47.4% in GDMT only; HR = 1.13 (95% CI: 0.81–1.56)] and the rate of death from any cause (24.3% vs. 22.4% in GDMT only; HR = 1.11 [95% CI: 0.69–1.77] between patients treated with MitraClip (device group [n = 152] baseline characteristics: LVEF: 33.3 ± 6.5%, LVEDV: 136.2 ± 37.4 ml/m2, NT-proBNP: 3,407 (1,948–6,790); see Table 1) and patients receiving GDMT only (15). The gene discussed is NPPB; the disease is hydrops fetalis.